- Dermira, Inc. (NASDAQ:DERM-OLD) announces several updates related to the upcoming launch and availability of QBREXZA (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. QBREXZA was approved by the FDA in June 2018.
- QBREXZA is expected to be available in pharmacies nationwide from October 1. QBREXZA will launch with a list price of $550 per 30-day supply. Two of the largest pharmacy benefit managers in the U.S., Express Scripts and OptumRx, have agreed to provide immediate coverage through their national formularies.
- To date, Dermira has secured contracted coverage for ~34% of the total U.S. commercial lives to date, with the goal of securing more than 50% coverage by January 1, 2019.
- Update: Shares are up 6% on below-average volume.